Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy
Primary Purpose
Epilepsy
Status
Suspended
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Vinpocetine
Sponsored by
About this trial
This is an interventional treatment trial for Epilepsy focused on measuring epilepsy, cognition, memory
Eligibility Criteria
Inclusion Criteria - Healthy (enrollment of healthy volunteers has been completed)
- Healthy adults 18-60 years old
- Proficient English
- Use of appropriate contraception if woman of childbearing potential. This must include complete abstinence for the duration of the study or use of a barrier method plus one other contraceptive method (e.g. hormonal contraception or intrauterine device, IUD).
Inclusion Criteria -Epilepsy
- Adults (18-60 years old) with localization related epilepsy
- Patient is on stable antiepileptic drug therapy for last 2 months and is willing to remain on same therapy for the duration of the study.
- Proficient English
- Patient complains of memory problems.
- Neurological Disorders Depression Index -Epilepsy (NDDI-E) score <16
- Mini-Mental Status Exam (MMSE) score <22
- No history of status epilepticus in last year
- No prior epilepsy surgeries
- Stable antiepileptic drug (AED) therapy for last 2 months or more and willing not to change for 2 months. Vinpocetine will be stopped and the patient will be withdrawn from the study if marked changes occur in seizures or if other adverse events occur.
- Use of appropriate contraception if woman of childbearing potential. This must include complete abstinence for the duration of the study or use of a barrier method plus one other contraceptive method (e.g. hormonal contraception or IUD).
Exclusion Criteria -Healthy:
- Major medical disease (e.g., epilepsy, diabetes, heart disease, active cancer, depression)
- Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.
- Use of centrally active medications
- History of allergy to vinpocetine
- Scores onintelligence quotient (IQ) <80 or Medical College of Georgia (MCG) Paragraph score < 2 standard deviations below norm.
- Pregnancy or lactation.
Exclusion Criteria- Epilepsy
- Major medical disease (e.g., diabetes, heart disease, active cancer, depression)
- Use of centrally active medications
- History of allergy to vinpocetine
- Progressive Cerebral Disease (e.g., Alzheimer's disease)
- Aphasia
- Taking more than 3 AEDs
- Pregnancy or lactation
- Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the C-SSRS at Screening.
Sites / Locations
- Stanford University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Placebo Comparator
Active Comparator
Arm Label
Low dose
Mid-dose 1
Placebo
High Dose
Arm Description
Vinpocetine 10 mg Healthy subjects
Vinpocetine 20mg Healthy subjects
0 dose of vinpocetine Healthy and Epilepsy subjects
Vinpocetine 60 mg single dose Healthy Subjects & 20mg tid Epilepsy Subjects
Outcomes
Primary Outcome Measures
Change in CNS Vitals Composite Score
CNS Vitals consists of multiple subtasks that provide an overall composite score will be the primary outcome measure
Secondary Outcome Measures
Adverse Events
safety outcome
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02011971
Brief Title
Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy
Official Title
Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Suspended
Why Stopped
We are now considering revision of the IND to determine maximum tolerated dose
Study Start Date
February 2012 (Actual)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Pilot studies in healthy volunteers and in patients with epilepsy to assess the potential efficacy and safety of different dosages of vinpocetine in improving cognition.
Detailed Description
Cognitive problems are common in patients with epilepsy, but there is currently no specific treatment available. Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drugs (i.e., carbamazepine, phenytoin, valproate, oxcarbazepine, lamotrigine and topiramate) in inhibiting both sodium and calcium channels, which control release of excitatory neurotransmitters that can lead to brain injury. Thus, vinpocetine might offer a unique drug to help cognition in patients with epilepsy. The investigators propose to conduct pilot studies in healthy volunteers and in patients with epilepsy to assess the potential efficacy and safety of different dosages of vinpocetine in improving cognition.
Specific Aim 1a: To determine if vinpocetine enhances memory and other cognitive functions in healthy volunteers.
Specific Aim 1b: To determine blood levels from 3 different acute oral doses of vinpocetine in healthy volunteers.
Specific Aim 2a: To provide safety and preliminary of efficacy data that vinpocetine can enhance memory and other cognitive functions in patients with epilepsy.
Specific Aim 2b: To determine blood levels from acute and chronic oral doses of vinpocetine in patients with epilepsy as well as effects on anticonvulsant blood levels.
Specific Aim 2c: To provide preliminary of data that vinpocetine can reduce seizure frequency or duration in patients with epilepsy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy
Keywords
epilepsy, cognition, memory
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Model Description
Double-blind single dose crossover with 1-month follow-up open label in patients.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Low dose
Arm Type
Active Comparator
Arm Description
Vinpocetine 10 mg Healthy subjects
Arm Title
Mid-dose 1
Arm Type
Active Comparator
Arm Description
Vinpocetine 20mg Healthy subjects
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
0 dose of vinpocetine Healthy and Epilepsy subjects
Arm Title
High Dose
Arm Type
Active Comparator
Arm Description
Vinpocetine 60 mg single dose Healthy Subjects & 20mg tid Epilepsy Subjects
Intervention Type
Drug
Intervention Name(s)
Vinpocetine
Other Intervention Name(s)
ethyl apovincaminate, ethyl apovincaminoate, eburnamenine-14-carboxylic acid ethyl ester, 3 alpha, 16 alpha-apovincaminic acid ethyl ester, ethyl apovincamin-22-oate, Cavinton®, Ceractin, ARGH-4405
Intervention Description
Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
Primary Outcome Measure Information:
Title
Change in CNS Vitals Composite Score
Description
CNS Vitals consists of multiple subtasks that provide an overall composite score will be the primary outcome measure
Time Frame
Healthy - weekly treatment visits 1-4; Epilepsy =treatment weeks 4, 8, & 12
Secondary Outcome Measure Information:
Title
Adverse Events
Description
safety outcome
Time Frame
Healthy - weekly treatment visits 1-4; Epilepsy =treatment weeks 4, 8, & 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria - Healthy (enrollment of healthy volunteers has been completed)
Healthy adults 18-60 years old
Proficient English
Use of appropriate contraception if woman of childbearing potential. This must include complete abstinence for the duration of the study or use of a barrier method plus one other contraceptive method (e.g. hormonal contraception or intrauterine device, IUD).
Inclusion Criteria -Epilepsy
Adults (18-60 years old) with localization related epilepsy
Patient is on stable antiepileptic drug therapy for last 2 months and is willing to remain on same therapy for the duration of the study.
Proficient English
Patient complains of memory problems.
Neurological Disorders Depression Index -Epilepsy (NDDI-E) score <16
Mini-Mental Status Exam (MMSE) score <22
No history of status epilepticus in last year
No prior epilepsy surgeries
Stable antiepileptic drug (AED) therapy for last 2 months or more and willing not to change for 2 months. Vinpocetine will be stopped and the patient will be withdrawn from the study if marked changes occur in seizures or if other adverse events occur.
Use of appropriate contraception if woman of childbearing potential. This must include complete abstinence for the duration of the study or use of a barrier method plus one other contraceptive method (e.g. hormonal contraception or IUD).
Exclusion Criteria -Healthy:
Major medical disease (e.g., epilepsy, diabetes, heart disease, active cancer, depression)
Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.
Use of centrally active medications
History of allergy to vinpocetine
Scores onintelligence quotient (IQ) <80 or Medical College of Georgia (MCG) Paragraph score < 2 standard deviations below norm.
Pregnancy or lactation.
Exclusion Criteria- Epilepsy
Major medical disease (e.g., diabetes, heart disease, active cancer, depression)
Use of centrally active medications
History of allergy to vinpocetine
Progressive Cerebral Disease (e.g., Alzheimer's disease)
Aphasia
Taking more than 3 AEDs
Pregnancy or lactation
Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the C-SSRS at Screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kimford J Meador, MD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford University
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy
We'll reach out to this number within 24 hrs